Industry Trends

While culture may "eat" strategy, shared understanding creates both culture and strategy, write Steve Figman and Sean Robertson.

The opioid crisis dominated the news in this year’s annual audit of press coverage of the pharmaceutical industry. Stephen J. Porth and George P. Sillup report.

The World Health Assembly's new resolution on transparency in the market for health-related products is weaker than the original draft but still contains measures that could have a substantial impact on market access around the world, writes Neil Grubert.

Findings support the belief that today’s pharma finance teams should be engaged across all functional areas, including regulatory, supply chain, manufacturing, and commercial. What does that mean for current and future CFOs in the industry?

The outlook for pharma M&A continues to be strong, writes Michael Jewell.

Stefan Spazek outlines the steps for biopharma startups in tapping non-dilutive financing options.

While gene therapies and cellular treatments are a boon for patients, they can be a financial bane for payers. Jane Barlow, Russell Teagarden, and Mark Trusheim outline alternative financing approaches, customizable for each payer’s needs and for each therapy’s characteristics.

The increase in new drug approvals and candidates in development are good signs for pharma and biotech, but both sectors face continued pricing, cost, and healthcare policy-related challenges ahead.

A growing range of MBAs with concentrations in pharmaceuticals and healthcare management are on offer. Pharm Exec look at how three of the top programs in the US prepare their students for industry success.

Pharm Exec’s latest company leaderboard in delivering shareholder value highlights the most critical measure of management performance-return on invested capital.

To succeed in developing targeted medicines, companies need a biomarker strategy and the expertise to make smart decisions about clinical trial design, assays, technology platforms and collaborative partners, write Barry S. Sall and Angela X. Qu.

The opioid crisis dominated the news in this year’s annual audit of press coverage of the pharmaceutical industry. George P. Sillup and Stephen J. Porth report.

Record capital flows across global public and private markets has opened up new channels of investment in early-stage and novel science.

Tommy Bramley and Kristine Flemister discuss today’s increasingly complex healthcare environment, and share insights into how stakeholders should be evolving to better help patients and providers navigate barriers around access and affordability.

Alison Horstmeyer discusses how pharma executives can apply four attributes of curiosity to negotiate VUCA (volatile, uncertain, complex, and ambiguous) conditions and improve organizational outcomes.

Azar and Gottlieb out front in revising rebates, restructuring Medicare, and promoting competition.

There is no magic bullet that will dramatically impact drug pricing to everybody’s liking. But a stepwise approach involving a series of reforms, including taking advantage of the next midterm elections, could point the path toward a solution.

Pharm Exec’s 18th annual listing of the top biopharma players shows that most of the familiar placeholders are holding their ground as they weigh a changing business climate with new opportunities for growth in a potentially resurgent marketplace.

Known as the city that never sleeps, attracting and keeping the scientific breakthroughs in-state is something that’s keeping New York economic and academic developers up at night.

Pharm Exec interviews the FDA commissioner, who is building support by combating opioid abuse and advancing innovation.

To coincide with World Immunization Week, IFPMA's Thomas Cueni, chair of the AMR Industry Alliance, outlines the critical importance of vaccines in the fight against AMR and infectious diseases.

With less than 50% of patients with long-term conditions remaining adherent to their recommended treatment, we need to look to behavioral science to deconstruct the barriers that make people act in ways that can seem self-defeating, writes Jim O'Donaghue.

Jo Pisani and Cynthia Chan outline the key legal considerations for post-deal integration.

Drawing from implementation lessons and successes in other industries, possible strategy shifts to pharma’s pricing playbook are explored.

Pharm Exec chronicles the military-industry effort to instill the principles of adaptive leadership into today’s pharma leader-a C-suite must in reviving the industry’s beleaguered reputation.